Olon Expands On Multiple Fronts
Adds To HPAPI Capabilities In India And Sets Out Investment Plans In Italy
Italian API and CDMO specialist Olon is expanding its high-potency capabilities at a site in India, at the same time as unveiling plans to invest a further €30m in a domestic biotech hub.
You may also be interested in...
Italy’s Olon expands through Indian plant
Italian active pharmaceutical ingredient (API) supplier and contract development and manufacturing organisation (CDMO) Olon has expanded its global footprint by striking a deal to buy an API facility in Mahad, India, from Novartis. Describing the plant as “established and reputable”, Olon noted that it “provides a number of lifesaving medicines to the Indian healthcare system and patients around the world”.
UAE’s Bioventure Is Looking For Partners To Expand
Having recently added to its biosimilars alliance with Alvotech, Dubai-based Bioventure says it is looking to expand its international reach through further partnerships.
Medicines For Europe Highlights Industry Agenda
Ahead of its annual meeting in Malta in mid-June, European off-patent industry association Medicines for Europe has set out the hot topics for generics and biosimilars stakeholders that delegates will be looking to discuss.